Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Haemonetics heads into its November 5 earnings date with short interest climbing sharply and options traders modestly more cautious, even as the Street remains broadly constructive on the name.
The short-side story is the most notable shift this week. Short interest has risen 27% over the past month to 7.5% of the free float, a meaningful build for a mid-cap medical device name. The week-on-week rise of 1.9% continues a trend that began in late September, when short positions jumped from around 2.9 million shares to above 3.5 million in just a few sessions. That cluster of new positioning coincided with the stock losing 3.4% on the week to close at $101.71, pulling it further below the Street's mean price target. Despite the build, the borrow market remains relaxed. Cost to borrow is a nominal 0.55%, and availability is enormous at roughly 3,593% of short interest, meaning there are more than 31 million shares available to lend against a short base of 3.5 million. No squeeze dynamics are in play.
Options positioning has nudged toward caution but stopped well short of alarm. The put/call ratio at 0.33 is about one standard deviation above its 20-day average of 0.27, a mild defensive tilt rather than a directional conviction signal. Context matters here: the PCR spent most of August and early September below 0.25, so even the current reading is low by historical standards. The 52-week high is 0.52. Investors are buying a little more protection than usual, not bracing for a move.
The Street leans bullish, though the most recent significant action is now three weeks old. Citigroup's Joanne Wuensch upgraded the stock to Buy on September 17, raising her target from $92 to $123. That followed a wave of post-earnings target increases in August from Baird, Barrington Research, BTIG and Raymond James, the latter lifting its Outperform target to $125. Against that backdrop, the consensus sits at five buys and two holds, with a mean target of $111.50. At $101.71, that implies about 10% upside. The bear case, as Benzinga frames it, centres on plasma franchise exposure to recombinant therapy substitution, execution risk in Interventional Technologies, and the cyclical nature of cardiology procedure volumes. Bulls point to F1Q revenue of $339.4 million, up 5.6% year on year, a six-cent EPS beat, and management's decision to raise FY2027 guidance to 5% to 8% revenue growth. Valuation multiples have eased over the past month: the PE has compressed by roughly 0.4 turns to 17.9x and EV/EBITDA has slipped to 11.7x, giving the stock a somewhat less stretched look than it carried through the summer. Forward EPS estimates rank in the 85th percentile for year-on-year increase, though the EV/EBIT factor scores near the bottom third of the universe at the 34th percentile.
On the ownership side, Neuberger Berman added 618,000 shares in August, making it the second-largest holder at 9.2% of shares. BlackRock, the largest at 13%, added 289,000 shares through September. Ariel Investments appears to have initiated a position of 4.5% reported as of June 30. Among the 13D/G register, no activist holder is present, all passive-style 13G filers, and stakes should be read as last disclosed around the 5% threshold.
Retail attention is running modestly above trend. Wikipedia page views for Haemonetics carry a z-score of 1.4 against the prior 90-day history, a soft signal of elevated interest rather than anything financial. There are no measured leading datasets in the ORTEX Alt Data coverage, so the November 5 print cannot be previewed through real-economy data. What the earnings history does show is a clean recent pattern: the August 2026 quarterly report produced a 5.1% one-day gain and an 8.1% five-day gain, the clearest data point available on how the market has rewarded a beat.
With the next print 28 days out, the question is whether the short rebuild over October reflects genuine fundamental scepticism or simply traders hedging against an elevated post-earnings bar, given a stock that has risen sharply year-to-date. The pace of short interest change relative to the still-loose borrow conditions will be worth tracking in the next two weeks.
See the live data behind this article on ORTEX.
Open HAE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
